# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Harriet Tubman (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI005-SYN-TD
- Date: 1897-05-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Carmen Ruiz-Delgado, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Results of ambulatory EEG and sleep studies; four-week headache check. **S**

## History of present illness

Mrs. Tubman returns for her test results and a headache check four weeks after starting candesartan 8 mg. Four of her typical spells were captured during the ambulatory EEG, and the overnight and daytime sleep studies are complete. Her sleep spells continue several times a day. Her headache diary shows fewer headache days than before, though still more than she would like, and she has used acetaminophen about once a week, with no ibuprofen since the first visit. She has had no dizziness on standing, swelling, or cough on candesartan. **S**

| Element | Detail |
|---|---|
| Testing completed | Ambulatory EEG with video, overnight polysomnography, and multiple sleep latency test |
| Sleep spells | Unchanged, several a day |
| Headache diary | Fewer headache days since starting candesartan; partial response |
| Acute medicine | Acetaminophen about once a week; no ibuprofen |
| Candesartan tolerance | No dizziness, swelling, or cough |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Neurological | Positive | Sleep spells several times a day; fewer headaches; no weakness or numbness |
| Cardiovascular | Negative | No palpitations, chest pain, or light-headedness on standing |
| Respiratory | Negative | No snoring or witnessed pauses in breathing reported; no cough |
| Psychiatric | Negative | Mood steady; no anxiety about the results |

4 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets by mouth as needed for headache, no more than 2 days a week **S**
- Candesartan 16 mg oral tablet, one tablet by mouth daily **S**
- Modafinil 100 mg oral tablet, one tablet by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 132/80 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 51.5 kg; BMI 22.3 kg/m². All vital signs are synthetic.

Sodium: 138 mmol/L; Potassium: 4.6 mmol/L; Creatinine: 0.9 mg/dL; eGFR: 67 mL/min/1.73 m²; Glucose: 94 mg/dL; PROMIS sleep-related impairment T-score: 67. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 138 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.6 mmol/L at this visit **S**
- Creatinine: 0.84 mg/dL at baseline, 0.9 mg/dL at this visit **S**
- eGFR: 72 mL/min/1.73 m² at baseline, 67 mL/min/1.73 m² at this visit **S**
- Glucose: 92 mg/dL at baseline, 94 mg/dL at this visit **S**
- PROMIS sleep-related impairment T-score: 68 at baseline, 67 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Alert; no spell during the visit |
| Cardiovascular | Regular rhythm; no edema |
| Neurological | Nonfocal; gait normal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Narcolepsy without cataplexy due to a medical condition, provisional** (G47.429). All four captured spells began at sleep onset with no ictal pattern, so they are sleep attacks, not seizures. Polysomnography showed REM sleep within 15 minutes of sleep onset and an apnea-hypopnea index of 4, excluding sleep apnea. The multiple sleep latency test showed a mean sleep latency of 4.5 minutes with two sleep-onset REM periods in five naps. With the overnight sleep-onset REM period this meets narcolepsy criteria; the diagnosis stays provisional because it follows a brain injury. PROMIS sleep-related impairment T-score 67. **S**
   - Start modafinil 100 mg each morning.
   - Two scheduled 15-minute naps a day.
   - Recheck blood pressure, heart rate, and PROMIS score at the three-month review.
2. **Chronic post-traumatic headache, partial response** (G44.329). Fewer headache days on candesartan 8 mg. Potassium 4.6 and creatinine 0.90 (eGFR 67) are stable; blood pressure 132/80 mmHg. **S**
   - Increase candesartan to 16 mg daily.
   - Judge the preventive effect at the three-month review.
3. **Medication-overuse headache** (G44.40). No ibuprofen for six weeks and acetaminophen about once a week; goal met. **S**
   - Keep acute medicine to no more than 2 days a week.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Ambulatory EEG with video | When routine EEG is not diagnostic | Completed today | Reviewed today: four typical spells captured, each at sleep onset with no ictal pattern |
| Examination | Overnight polysomnography and multiple sleep latency test | For excessive daytime sleepiness | Completed today | Reviewed today: apnea-hypopnea index 4; mean sleep latency 4.5 minutes with two sleep-onset REM periods |
| Medication safety | Antiseizure medicine | Only if spells prove epileptic | Not indicated | Spells are sleep attacks; no antiseizure medicine |
| Survey | PROMIS sleep-related impairment | At baseline and after treatment | Completed today | T-score 67, little changed from 68 before treatment |
| Medication safety | Modafinil: blood pressure and heart rate | Before starting and at follow-up | Completed today | Baseline 132/80 mmHg, pulse 72; started today at 100 mg for an older adult |
| Laboratory | Basic metabolic panel (potassium and creatinine) on candesartan | Before starting and a few weeks after; then periodically | Completed today | Four weeks after starting: potassium 4.6, creatinine 0.90, eGFR 67, sodium and glucose normal |
| Examination | Blood pressure, heart rate, and weight | Every visit | Completed today | 132/80 mmHg, pulse 72, weight 51.5 kg |
| Self-management | Headache diary (headache days and acute-medicine days) | Daily | Completed today | Reviewed; fewer headache days since starting candesartan |
| Medication safety | Acute headache medicine on no more than 2 days a week | Every visit | Completed today | Acetaminophen about once a week; no ibuprofen |
| Survey | Headache days per three months | 2 to 3 months after starting prevention | Due | At the three-month review |
| Self-management | Safety advice for sudden sleep episodes | Every visit | Completed today | Reviewed; scheduled naps added |
| Survey | Depression screen (PHQ-9) | At baseline and at follow-up | Due | At the three-month review |

## Goal progress

- Stop daily over-the-counter analgesics and limit acute headache medicine to no more than 2 days a week. Outcome by 1897-05-18: No ibuprofen since the first visit; acetaminophen about once a week. **S**
- Cut headache days by at least half by the three-month review. In progress; target 1897-08-17. **S**
- Reduce daytime sleep attacks and lower the PROMIS sleep-related impairment T-score below 60. In progress; target 1897-08-17. **S**
- Establish whether the spells are epileptic before considering antiseizure medicine. Outcome by 1897-05-18: Typical spells captured on ambulatory EEG were sleep onset; no antiseizure medicine needed. **S**

## Medication changes

- Stopped: Candesartan 8 mg oral tablet, one tablet by mouth daily **S**
- Started: Candesartan 16 mg oral tablet, one tablet by mouth daily **S**
- Started: Modafinil 100 mg oral tablet, one tablet by mouth each morning **S**

## Guideline basis

- Evidence-based guideline: Management of an unprovoked first seizure in adults (Krumholz A, et al. Neurology 2015;84(16):1705-1713) (2015), American Academy of Neurology and American Epilepsy Society
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline (Maski K, et al. J Clin Sleep Med 2021;17(9):1881-1893) (2021), American Academy of Sleep Medicine
- The International Classification of Headache Disorders, 3rd edition (Cephalalgia 2018;38(1):1-211) (2018), Headache Classification Committee of the International Headache Society
- The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (Ailani J, et al. Headache 2021;61(7):1021-1039) (2021), American Headache Society

## Follow-up

- Three-month sleepiness and headache review with potassium and creatinine, PROMIS score, headache-day count, and PHQ-9. **S**
- Next scheduled visit 1897-08-17: three-month sleepiness and headache review. **S**
